Log in

ASX:CP1Cannpal Animal Therapeutics Stock Price, Forecast & News

A$0.09
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.09
Now: A$0.09
A$0.09
50-Day Range
A$0.07
MA: A$0.09
A$0.10
52-Week Range
A$0.07
Now: A$0.09
A$0.20
VolumeN/A
Average VolumeN/A
Market Capitalization$8.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CannPal Animal Therapeutics Limited, a pet pharmaceutical company, engages in the research and development of animal health products in Australia. It offers regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with therapeutics to treat animals. The company was incorporated in 2016 and is based in Double Bay, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 6108 3622

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$654,421.00
Cash FlowA$0.03 per share
Book ValueA$0.03 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$8.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CP1 News and Ratings via Email

Sign-up to receive the latest news and ratings for CP1 and its competitors with MarketBeat's FREE daily newsletter.

Cannpal Animal Therapeutics (ASX:CP1) Frequently Asked Questions

How has Cannpal Animal Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cannpal Animal Therapeutics' stock was trading at A$0.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CP1 stock has decreased by 29.6% and is now trading at A$0.09. View which stocks have been most impacted by Coronavirus.

Has Cannpal Animal Therapeutics been receiving favorable news coverage?

Press coverage about CP1 stock has trended somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cannpal Animal Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutCannpal Animal Therapeutics.

Who are some of Cannpal Animal Therapeutics' key competitors?

Who are Cannpal Animal Therapeutics' key executives?

Cannpal Animal Therapeutics' management team includes the following people:
  • Mr. Layton Patrick Mills, Founder, MD & Director
  • Dr. Margaret Curtis, Head of Clinical Devel. and R&D
  • Mr. Baden Maxwell Bowen, CFO & Company Sec.
  • Dr. Rayson Tan, Chief Scientific Officer & Member of Advisory Board

What is Cannpal Animal Therapeutics' stock symbol?

Cannpal Animal Therapeutics trades on the ASX under the ticker symbol "CP1."

What is Cannpal Animal Therapeutics' stock price today?

One share of CP1 stock can currently be purchased for approximately A$0.09.

How big of a company is Cannpal Animal Therapeutics?

Cannpal Animal Therapeutics has a market capitalization of $8.20 million and generates $654,421.00 in revenue each year.

What is Cannpal Animal Therapeutics' official website?

The official website for Cannpal Animal Therapeutics is www.cannpal.com.

How can I contact Cannpal Animal Therapeutics?

The company can be reached via phone at 61 2 6108 3622.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.